High-performance liquid chromatographic separation and electrochemical or spectrophotometric determination of R(-)N-n-propylnorapomorphine and R(-)10,11-methylenedioxy-N-n-propylnoraporphine in primate plasma.
The dopamine receptor agonist R(-)N-n-propylnorapomorphine (NPA) and its proposed pro-drug R(-)10,11-methylenedioxy-N-n-propylnoraporphine (MDO-NPA) were isolated simultaneously from monkey plasma using a solid-phase extraction procedure. R(-)Apomorphine (APO) and R(-)10,11-methylenedioxyaporphine (MDO-APO) were added as internal standards, and separation and quantification were by high-performance liquid chromatography with electrochemical or ultraviolet detection of the free catechol and MDO compounds, respectively. The detection limits for NPA and MDO-NPA in plasma were 0.5 and 10 ng/ml and the coefficient of variation (S.D./mean) within assays and between days of assays for both drugs was 5.6% or less. Quantification of plasma levels of NPA and MDO-NPA was possible at ranges of 2-1000 and 40-5000 ng/ml, respectively, including concentrations found after intravenous administration of these agents.
Lampen
P
P
Section of Medicinal Chemistry, College of Pharmacy and Allied Health Professions, Northeastern University, Boston, MA 02115.
Neumeyer
J L
JL
Baldessarini
R J
RJ
D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D001060:Aporphines / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D004563:Electrochemistry; D008252:Macaca fascicularis; D013056:Spectrophotometry, Ultraviolet
D001060:Aporphines; C009074:N-n-propylnorapomorphine; C033829:10,11-methylenedioxy-N-propylnoraporphine; D001058:Apomorphine